Search NASA⌕ Search

SEARCH · Search NASA

Results for “therapy”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 343 records · Page 19
All sourcesNASA NTRSDOE OSTI
NASA NTRS2001

Method and apparatus for guiding ablative therapy of abnormal biological electrical excitation

This invention involves method and apparatus for guiding ablative therapy of abnormal biological electrical excitation. In particular, it is designed for treatment of cardiac arrhythmias. In the method of this invention electrical signals are acquired from passive electrodes, and an inverse dipole method is used to identify the site of origin of an arrhytmia. The location of the tip of the ablation catheter is similarly localized from signals acquired from the passive electrodes while electrical energy is delivered to the tip of the catheter. The catheter tip is then guided to the site of origin of the arrhythmia, and ablative radio frequency energy is delivered to its tip to ablate the site.

Armoundas, Antonis A.↗
NASA NTRS2010

Method and apparatus for the guided ablative therapy of fast ventricular arrhythmia

Method and apparatus for guiding ablative therapy of abnormal biological electrical excitation. The excitation from the previous excitatory wave is significant at the beginning of the next excitation. In particular, it is designed for treatment of fast cardiac arrhythmias. Electrical signals are acquired from recording electrodes, and an inverse dipole method is used to identify the site of origin of an arrhythmia. The location of the tip of an ablation catheter is similarly localized from signals acquired from the recording electrodes while electrical pacing energy is delivered to the tip of the catheter close to or in contact with the cardiac tissue. The catheter tip is then guided to the site of origin of the arrhythmia, and ablative radio frequency energy is delivered to its tip to ablate the site.

Cohen, Richard J.↗
DOE OSTI2021

Small molecule dye for molecular imaging and photothermal therapy

Disclosed is a small molecule dye for use in imaging in the near-infrared window, namely between 1000 nm-1700 nm wavelength. The present dyes are also useful for photoacoustic imaging and photothermal therapy. The dyes have a structure of a D-A-D (donor-acceptor-donor) fluorescent compound core and side chains rendering the compounds water soluble and easily conjugated to hydrophilic polymers and/or targeting ligands. Further disclosed is compound, CH1055 that can be PEGylated, conjugated to a targeting ligand, or conjugated to taurine. Key steps utilized to assemble the core structure of the target included a cross-Suzuki coupling reaction, iron reduction and N-thionylaniline induced ring closure. Four carboxylic acid groups were introduced into the donor-acceptor-donor (D-A-D) type fluorescent compound to impart a certain aqueous solubility and to allow facile conjugation to targeting ligands.

Cheng, Zhen↗
DOE OSTI2021

Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the drug's mechanism of action

Repurposed drugs that are safe and immediately available constitute a first line of defense against new viral infections. Despite limited antiviral activity against SARS-CoV-2, several drugs are being tested as medication or as prophylaxis to prevent infection. Using a stochastic model of early phase infection, we evaluate the success of prophylactic treatment with different drug types to prevent viral infection. We find that there exists a critical efficacy that a treatment must reach in order to block viral establishment. Treatment by a combination of drugs reduces the critical efficacy, most effectively by the combination of a drug blocking viral entry into cells and a drug increasing viral clearance. Below the critical efficacy, the risk of infection can nonetheless be reduced. Drugs blocking viral entry into cells or enhancing viral clearance reduce the risk of infection more than drugs that reduce viral production in infected cells. The larger the initial inoculum of infectious virus, the less likely is prevention of an infection. In our model, we find that as long as the viral inoculum is smaller than 10 infectious virus particles, viral infection can be prevented almost certainly with drugs of 90% efficacy (or more). Even when a viral infection cannot be prevented, antivirals delay the time to detectable viral loads. The largest delay of viral infection is achieved by drugs reducing viral production in infected cells. A delay of virus infection flattens the within-host viral dynamic curve, possibly reducing transmission and symptom severity. Thus, antiviral prophylaxis, even with reduced efficacy, could be efficiently used to prevent or alleviate infection in people at high risk.

59 BASIC BIOLOGICAL SCIENCES↗
NASA NTRS1998

Evaluation of pGL1-TNF-alpha therapy in combination with radiation

Long-term control of high-grade brain tumors is rarely achieved with current therapeutic regimens. In this study a new plasmid-based human tumor necrosis factor-alpha (TNF-alpha) expression vector was synthesized (pGL1-TNF-alpha) and evaluated together with radiation in the aggressive, rapidly growing C6 rat glioma model. pGL1-TNF-alpha was successfully transfected into C6 cells in vitro using a cationic polyamine method. Expression was detected up to 7 days and averaged 0.4 ng of TNF-alpha in the culture medium from 1x10(5) cells. The expressed protein was biologically functional, as evidenced by growth inhibition of L929, a TNF-alpha-susceptible cell line. Using fluorescence-labeled monoclonal antibodies and laser scanning cytometry, we confirmed that both the P55 and P75 receptors for TNF-alpha were present on the C6 cell membrane. However, the receptors were present at low density and P55 was expressed more than the P75 receptor. These findings were in contrast to results obtained with TNF-alpha-susceptible L929 cells. Tests in athymic mice showed that pGL1-TNF-alpha administered intratumorally 16-18 h before radiation (each modality given three times) significantly inhibited C6 tumor progression (P<0.05). This effect was more than additive, because pGL1-TNF-alpha alone did not slow tumor growth and radiation alone had little effect on tumor growth. These results indicate that pGL1-TNF-alpha has potential to augment the antitumor effects of radiation against a tumor type that is virtually incurable.

Non-NASA Center↗
DOE OSTI2020

Amorphous Ag 2-x Cu x S quantum dots: “all-in-one” theranostic nanomedicines for near-infrared fluorescence/photoacoustics dual-modal-imaging-guided photothermal therapy

Integrating dual-modal imaging and photothermal effect within a single nanosystem is an enormous challenge for current nanomedicine application. In this study, non-toxic amorphous Ag 2-x Cu x S quantum dots (QDs) possessing near-infrared fluorescence (NIRF), enhanced photothermal and photoacoustic (PA) performance, as “one-in-all” nanomedicines, are designed and obtained. Cu doping in amorphous Ag 2 S QDs causes red-shift of NIRF to the lowest tissue absorption wavelength in so called “first biowindow” (~820 nm) and improves photothermal conversion efficiency to 44.0% simultaneously. Density functional theory simulation results suggest the fluorescence red-shift and enhanced photothermal/photoacoustics properties can be attributed to the generation of intragap states introduced by Cu doping. The amorphous Ag 2-x Cu x S QDs exhibit high long-term biocompatibility. Under a single laser irradiation with relatively low power density, an effective tumor ablation induced by high photothermal effect of amorphous Ag 2-x Cu x S QDs is achieved in vivo. Simultaneously, the PTT process can be guided by high quality NIRF/PA dual-modal-imaging.

36 MATERIALS SCIENCE↗
DOE OSTI2025

Correction to “From Structure to Function: Zn/Mn-Modified Maghemite as an Advanced Nanoplatform for Magnetic Hyperthermia and Radionuclide Therapy”

In the original paper, the acknowledgment contained an error in the attribution of the financial support. The correction is necessary to accurately reflect the source of funding that supported the contributions of the authors from the Institute of Physics Belgrade. The corrected Acknowledgments section is below. Here, this correction pertains solely to the funding acknowledgment and does not affect the scientific content, data, results, or conclusion of the work in any way.

Cancer therapy↗
DOE OSTI2021

A proton beam energy modulator for rapid proton therapy

We present the design for a rapid proton energy modulator with radiofrequency accelerator cavities, which can deliver the proton radiation dose to varied depth in human tissues much faster than traditional mechanical beam energy degraders. The proton energy modulator is designed as a multi-cell 1-m long accelerator working at 2.856 GHz. Each individual accelerator cavity is powered by a 400 kW compact klystron to provide an accelerating/decelerating gradient of 30 MV/m. The high gradient is enabled by the individual power coupling regime, which provides a high shunt impedance. Beam dynamics simulations were performed, showing that the energy modulator can provide ±30 MeV of beam energy change for a 150 MeV, 7 mm long (full length) proton bunch, and the total energy spread of 3 MeV is satisfactory to clinical needs. A prototype experiment of a single cell has been built and tested, and the low-power microwave measurement results agree very well with simulations. The energy modulator is optimized for the 150 MeV cyclotron proton beam, while this approach can work with different beam energies.

47 OTHER INSTRUMENTATION↗
DOE OSTI2020

Production of Radiohalogens: Bromine and Astatine for Imaging and Therapy

Over the course of this two year grant, we have developed and optimized new methods for the production of clinical quality 76 Br, 77 Br, and 80m Br at the University of Wisconsin. This includes the synthesis of a novel isotopically enriched cobalt-selenium intermetallic compound, its fabrication into robust cyclotron targets, and the chemical isolation of the resulting bromine radionuclide. Compared with the previous state-of-the-art, these methods demonstrate a six-times larger 76 Br and three-times larger 77 Br production capacity for a 3-hour cyclotron irradiation. Additionally, the cyclotron targets are exceptionally robust to this process, allowing for their reuse for dozens of radiobromine productions.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗
DOE OSTI2024

Ligand design in lanthanide complexes for luminescence, therapy, and sensing

In this chapter, we explore the research done by the de Bettencourt-Dias group in luminescent lanthanide complexes. The group has isolated ligands that sensitize the luminescence of lanthanide ions, and that bear additional functional groups that impart unique properties to the resulting complexes, such as the ability to generate cytotoxic singlet oxygen, or report on, through changes in emission intensity, viscosity or temperature at the nanoscale. The energy transfer processes are accessed through one-photon excitation or two-photon excitation through the ligand, as well as upconversion. Moreover, the group explored unique coordination chemistry of lanthanides, taking advantage of secondary interactions to isolate outer-sphere complexes of these ions.

Barber, Patrick S.↗